Safety of pregnancy in acromegaly patients and maternal and infant outcomes after pregnancy: single-center experience from China and review of the literature

Table 4 Disease condition and treatment after delivery in patients with acromegaly and clinical characteristics at last follow-up

No	Before pregnancy		Follow up after last pregnancy (months)	Biochemical examination at last follow-up			Acromegalic treatment after pregnancy			Clinical characteristics at last follow-up
No	Acromegaly control	Medical therapy	Follow up after last pregnancy (months)	GH (µg/L)	IGF-1 (ng/ml)	IGF-1 (ULN)	Surgery	Radiotherapy	Medical therapy	Acromegaly control	HTN	DM
1	Yes	Oct Lan	32	0.7	191	0.71	No	No	No	Yes	No	No
2	No	Oct	86	0.639^a	111.6	0.36	Yes	SFRT	Oct	Yes	No	No
3	No	No	93	0.9	216	0.76	Yes	SFRT	Br Oct	Yes	No	No
4	Yes	Br Pas	35	3.4	289	0.87	No	No	Br Cab	Yes	No	No
5	Yes	Oct	3	0.3	303	0.92	No	No	No	Yes	No	No
6	Yes	No	14	0.932^a	441	1.34	No	No	No	Yes	No	No
7	No	Oct	18	3.9	471	1.53	No	Cyber knife	Oct	No	Yes	No
8	No	No	26	4.01^a	845	2.78	No	No	No	No	Yes	Yes

ULN, percentage of the upper limit of normal range of IGF-1; SFRT, single-fraction radiotherapy; Oct, Octreotide; Br, Bromocriptine; Cab, Cabergoline; HTN, hypertension; DM, diabetes mellitus.
^a: Nadir GH with OGTT.

ISSN: 1472-6823